Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 2/20 | 0.44 |
| ▸ | FNTA | P49354 | 3/20 | 0.43 |
| ▸ | FNTB | P49356 | 3/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966575 | 0.91 | FNTA (0.49) | FNTAFNTBPGGT1BMMP1MMP3 | |
| SCHEMBL5966483 | 0.90 | CTSL (0.43) | BIRC2SSTR3 | |
| SCHEMBL5966592 | 0.86 | SSTR3 (0.47) | SSTR3BMP1 | |
| SCHEMBL5966565 | 0.83 | CTSS (0.49) | SSTR3 | |
| SCHEMBL5966675 | 0.80 | REN (0.44) | SSTR3F2CA1CA2BMP1 | |
| SCHEMBL5966526 | 0.80 | F2 (0.42) | SSTR3F2 | |
| SCHEMBL5966488 | 0.79 | SSTR3 (0.41) | BIRC2SSTR3MMP1MMP3MMP9 | |
| SCHEMBL5966476 | 0.79 | BIRC2 (0.44) | BIRC2SSTR3MMP1MMP3MMP9 | |
| SCHEMBL5966597 | 0.79 | GNPAT (0.45) | FNTAFNTBPGGT1BMMP1MMP3 | |
| SCHEMBL5966622 | 0.79 | GNPAT (0.45) | FNTAFNTBPGGT1BMMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128613-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1409540-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002026774-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128613-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | BIRC2 4708/4885FNTA 4205/4885FNTB 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.